对MASH的药理疗法在降低肝脂肪含量的比较有效性:系统性审查和网络元分析
Benjamin Koh1, Jieling Xiao1, Cheng Han Ng2,3
1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Hepatology (Baltimore, Md.)
|July 19, 2024
概括
阿尔达菲尔明和佩戈扎菲尔明在患有代谢功能障碍相关的脂肪肝炎 (MASH) 的患者中显示出降低肝脂肪的最高疗效. 这一系统性审查对MASH的疗法进行了排名,有助于未来的临床试验设计和治疗选择.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 放射学 放射学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是肝脏疾病的重要原因.
- 磁共振成像 (MRI) 质子密度-脂肪分数 (PDFF) 的变化与MASH分辨率相关.
- 准确评估MASH治疗效果至关重要.
研究的目的:
- 进行系统性审查和网络元分析,以确定药理学药物的相对有效性,以减少肝脏脂肪.
- 评估使用MRI-PDFF作为主要结果指标的治疗干预措施.
- 根据它们在减少肝脂肪方面的有效性,提供MASH疗法的更新排名.
主要方法:
- 系统地搜索MEDLINE和Embase数据库,直到2023年12月26日,进行随机对照试验 (RCT).
- 包括评估MASH的药理干预措施的RCT,以MRI-PDFF作为结果.
- 网络元分析和曲线下的表面累积排名概率 (SUCRA) 分析来对干预进行排名.
主要成果:
- 包括39个RCT,共3311名参与者.
- 在24周,阿尔达费尔明 (SUCRA: 83.65) 和佩戈扎费尔明 (SUCRA: 83.46) 是对MRI-PDFF下降最有效的.
- 为了在24周内实现MRI-PDFF≥30%的下降,efinopegdutide,semaglutide + firsocostat和pegbelfermin显示出高效率.
结论:
- 这项研究提供了MASH疗法的相对疗效排名,以减少肝脏脂肪.
- 这些发现可以为未来临床试验的设计和样本大小计算提供信息.
- 数据可以帮助临床医生选择MASH的最佳疗法和组合治疗方法.
更多相关视频
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
11.9K
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.0K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
621
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
621
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
37
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
37